

Union Calendar No. 629

119TH CONGRESS
2^D SESSION

H. R. 5160

[Report No. 119-724]

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 4, 2025

Mr. SMITH of New Jersey (for himself, Ms. MATSUI, Mr. BILIRAKIS, Ms. PINGREE, Ms. TENNEY, and Mr. MFUME) introduced the following bill; which was referred to the Committee on Energy and Commerce

JULY 2, 2026

Additional sponsors: Mrs. FISCHBACH, Mrs. DINGELL, Mr. GOTTHEIMER, Mr. ADERHOLT, Ms. MALLIOTAKIS, Ms. CASTOR of Florida, Mr. GARBARINO, Ms. NORTON, Mr. BENTZ, Ms. BARRAGÁN, Mr. FINSTAD, Ms. MORRISON, Mr. LAWLER, Mr. VINDMAN, Mr. FITZPATRICK, and Ms. DAVIDS of Kansas

JULY 2, 2026

Reported with an amendment, committed to the Committee of the Whole
House on the State of the Union, and ordered to be printed

[Strike out all after the enacting clause and insert the part printed in *italic*]

[For text of introduced bill, see copy of bill as introduced on September 4, 2025]

A BILL

To reauthorize the Stem Cell Therapeutic and Research Act
of 2005, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
 2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 *This Act may be cited as the “Stem Cell Therapeutic*
 5 *and Research Reauthorization Act of 2025”.*

6 **SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL**
 7 **TRANSPLANTATION PROGRAM.**

8 *Section 379B of the Public Health Service Act (42*
 9 *U.S.C. 274m) is amended—*

10 *(1) by striking “appropriated \$31,009,000” and*
 11 *inserting the following: “appropriated—*

12 *“(1) \$31,009,000”;*

13 *(2) in paragraph (1), as so inserted, by striking*
 14 *the period at the end and inserting “; and”; and*

15 *(3) by adding at the end the following:*

16 *“(2) \$33,009,000 for each of fiscal years 2027*
 17 *through 2031.”.*

18 **SEC. 3. CORD BLOOD INVENTORY.**

19 *(a) IN GENERAL.—Section 2(a) of the Stem Cell*
 20 *Therapeutic and Research Act of 2005 (42 U.S.C. 274k*
 21 *note) is amended by striking “at least 150,000 new units*
 22 *of high-quality cord blood” and inserting “a sufficient sup-*
 23 *ply, as determined by the Secretary, of high-quality cord*
 24 *blood units”.*

1 (b) *APPLICATION*.—Section 2(c) of such Act (42 U.S.C.
2 274k note) is amended—

3 (1) in paragraph (2), by striking “in perpetuity
4 or”; and

5 (2) by amending paragraph (5) to read as fol-
6 lows:

7 “(5) if the Secretary determines through an as-
8 sessment, or through petition by the applicant, that a
9 cord blood bank is no longer operational, does not
10 meet the requirements described in subsection (d)(4),
11 or does not meet the requirements of section 379(d)(4)
12 of the Public Health Service Act, and as a result may
13 not distribute the high-quality units, the Secretary
14 may transfer the units collected pursuant to this sec-
15 tion to another qualified cord blood bank or entity
16 approved by the Secretary to ensure continued avail-
17 ability of high-quality cord blood units.”.

18 (c) *DURATION OF CONTRACTS*.—Section 2(d)(4) of
19 such Act (42 U.S.C. 274k note) is amended to read as fol-
20 lows:

21 “(4) *CONSIDERATION OF BEST SCIENCE*.—The
22 Secretary shall take into consideration current sci-
23 entific and clinical information in order to maximize
24 the availability of high-quality cord blood units meet-
25 ing applicable clinical and quality standards for

1 *transplant when entering into contracts under this*
2 *section, or when extending a period of funding under*
3 *such a contract under paragraph (2).”.*

4 *(d) INVENTORY MANAGEMENT.—Section 2 of such Act*
5 *(42 U.S.C. 274k note) is amended—*

6 *(1) by redesignating subsections (e), (f), and (g)*
7 *and as subsections (f), (g), and (h), respectively; and*

8 *(2) by inserting after subsection (d) the fol-*
9 *lowing:*

10 *“(e) INVENTORY MANAGEMENT.—*

11 *“(1) IN GENERAL.—The Secretary shall manage*
12 *the size and composition of the National Cord Blood*
13 *Inventory to maximize clinical utility, ensure genetic*
14 *diversity, and promote the efficient use of resources.*

15 *“(2) CONSIDERATIONS.—In carrying out para-*
16 *graph (1), the Secretary may—*

17 *“(A) on the Secretary’s own initiative or*
18 *upon petition by a qualified cord blood bank,*
19 *make determinations regarding the continued*
20 *storage of cord blood units based on the best*
21 *available scientific and clinical evidence; or*

22 *“(B) prioritize the collection, retention, or*
23 *disposition of cord blood units based on sci-*
24 *entific, clinical, or operational considerations*
25 *that the Secretary determines to be relevant.”.*

1 (e) *DEFINITIONS.*—Section 2(g) of such Act, as redesign-
2 nated by subsection (d)(1) of this section, is amended—

3 (1) by redesignating paragraphs (4) and (5) as
4 paragraphs (5) and (6), respectively; and

5 (2) by inserting after paragraph (3) the fol-
6 lowing:

7 “(4) The term ‘high quality cord blood unit’
8 means a cord blood unit that meets current industry
9 standards and any requirements of the Food and
10 Drug Administration.”.

11 (f) *AUTHORIZATION OF APPROPRIATIONS.*—Section
12 2(h) of such Act, as redesignated by subsection (d)(1) of this
13 section, is amended by striking “fiscal years 2022 through
14 2026” and inserting “fiscal years 2027 through 2031”.

Union Calendar No. 629

119TH CONGRESS
2D Session

H. R. 5160

[Report No. 119-724]

A BILL

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

JULY 2, 2026

Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed